Key Highlights
- Serina Therapeutics shares rocketed 39.45% in extended trading to $1.78 from a regular session closing price of $1.28.
- The biotechnology firm disclosed a $15 million initial private placement scheduled to close March 20, with an additional $15 million tranche potentially closing by April 30.
- Full warrant exercise could generate an extra $33.3 million, potentially funding operations through late 2027.
- The financing is structured at $2.25 per share — representing a 68% premium over the March 17 close.
- Greg Bailey, board member with ties to Pfizer’s $11.6B Biohaven purchase and $14B Medivation acquisition, will assume Co-Chairman role.
Serina Therapeutics (SER) experienced a dramatic 40% surge during after-hours trading Wednesday following the clinical-stage biotech’s announcement of a private placement that could ultimately generate up to $63.3 million.
Serina Therapeutics, Inc., SER
The dramatic after-market movement occurred when Serina disclosed that the initial $15 million funding tranche is set to close March 20, 2026. An additional tranche worth up to $15 million could close on or before April 30.
Shares climbed from their regular trading session close of $1.28 — which reflected a 4.48% daily decline — to $1.78 in extended hours.
The offering carries a price tag of $2.25 per share, marking a substantial 68% premium relative to the March 17 closing level. Each share or pre-funded warrant includes a half-warrant granting the right to purchase additional stock at $5.00 per share. These warrants extend four years and, upon full exercise, could contribute another $33.3 million, elevating the total potential capital raised to $63.3 million.
This runway extension proves critical for a clinical-stage biotechnology company. According to Serina, the capital infusion would sustain operations through the second half of 2027.
Biotech Veteran Assumes Leadership Position
The financing round is spearheaded by Greg Bailey, M.D., a sitting board member who will transition into the Co-Chairman position alongside current chair Simba Gill, Ph.D.
Bailey arrives with an impressive investment pedigree. He was an early investor in Biohaven Ltd., which Pfizer acquired in 2022 for roughly $11.6 billion, and Medivation, which Pfizer purchased in 2016 for $14 billion.
This background resonated with market participants. When a figure like Bailey leads a financing arrangement, particularly in the biotechnology sector, it typically signals confidence and can significantly influence investor sentiment.
Capital Deployment Strategy
The raised capital will support Serina’s SER-252 registrational study, an active Phase 1b clinical trial focused on advanced Parkinson’s disease. Patient enrollment is underway at clinical sites throughout Australia and the United States.
SER-252 is advancing through the FDA’s 505(b)(2) regulatory framework, which CEO Steve Ledger characterized as “capital-efficient.” The study has already dosed its first patient.
Serina anticipates that safety data from Cohort 1 will enable progression to Cohort 2 during Q3 2026. Topline data from the single-ascending dose portion of the trial is expected in the first half of 2027.
The therapeutic candidate addresses an estimated 250,000 advanced Parkinson’s disease patients across the U.S. and Europe whose symptoms are insufficiently managed by existing therapeutic options.
Notwithstanding Wednesday’s after-hours rally, SER’s broader performance trajectory remains concerning. The stock trades within a 52-week range spanning $1.22 to $7.92 and has tumbled 71.11% over the trailing twelve months. The company maintains a market capitalization of merely $13.65 million, while its RSI registers at 29.86 — indicating deeply oversold technical conditions.
SER concluded Wednesday’s regular trading session at $1.28, declining 4.48% intraday.
